TrialScope has acquired Clinical Trial Connect, a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. As part of the acquisition, founder Mike Wenger will share his technological expertise as part of the TrialScope team.
This acquisition delivers rapid innovation to the clinical trial community. The combination of TrialScope and Clinical Trial Connect helps close the gap on some of the industry’s biggest recruiting challenges: structuring of complex clinical trial data, trial data accuracy, and availability and improved trial matching for patients, clinicians and other healthcare providers.
“The acquisition of Clinical Trial Connect further strengthens TrialScope’s commitment to clinical trial disclosure, data sharing and patient engagement,” said CEO Jeff Kozloff. “Mike Wenger has built an impressive technology platform that numerous advocacy groups deploy to help their members quickly and accurately match to relevant clinical trial options. This adds fuel to our innovation engine as we work to shift perception of transparency from a regulatory requirement to a strategic advantage.”
Similar to TrialScope Engage™, powering clinical trial websites with robust data automation and search functionality, Clinical Trial Connect matches patients searching online for clinical trials. While the goal of both platforms is to help patients find clinical trials, TrialScope Engage™ does so via sponsor websites; Clinical Trial Connect reaches patients through advocacy sites.
“TrialScope processes a jaw-dropping amount of data that is posted to ClinicalTrials.gov, over 40 percent of all industry studies,” said Wenger. “This reach, coupled with a customer roster of more than 25 of the world’s largest pharmaceutical sponsors, makes TrialScope the perfect home for Clinical Trial Connect’s technology. Together, we’ll reach and serve more life sciences companies, patients and families with tools to accelerate clinical trial searching and recruiting.”